Year: 2019

BerGenBio presents preliminary Phase II clinical data at EHA 24: bemcentinib in combination with low dose chemotherapy yields durable responses in AML patients unfit for intensive chemotherapy

June 14, 2019

Two posters to be presented at the 2019 annual congress of the European Hematology Association…

Read More

BerGenBio presents new Phase II clinical data that bemcentinib in combination with low dose chemotherapy improves efficacy and duration of survival in elderly AML patients at ASCO 2019

June 3, 2019

  Phase II trial evaluating bemcentinib in combination with low-intensity chemotherapy n elderly AML patients…

Read More

BerGenBio presents new preliminary clinical and biomarker data showing durable response & median survival rates in Phase II trial with bemcentinib and KEYTRUDA in patients with advanced NSCLC at ASCO 2019

June 2, 2019

Phase II trial evaluating bemcentinib in combination with KEYTRUDA in advanced NSCLC patients shows 12-month…

Read More

BERGENBIO ASA: INVITATION TO ASCO UPDATE CALL

May 31, 2019

Bergen, Norway, 31 May 2019 – BerGenBio ASA (OSE:BGBIO), will share its latest updates and data…

Read More

BerGenBio to present new NSCLC and AML clinical data and biomarker data from Phase II development programme with selective AXL inhibitor bemcentinib at ASCO 2019

May 15, 2019

Two peer reviewed abstracts on Phase II clinical data with bemcentinib accepted for presentation at…

Read More

BerGenBio completes recruitment into second stage of Phase II trial with selective AXL inhibitor bemcentinib in combination with KEYTRUDA® in patients with advanced NSCLC

May 8, 2019

Phase II, Simon two-stage trial evaluating bemcentinib and KEYTRUDA in previously treated NSCLC post chemotherapy…

Read More